Diagnostic News and Research

RSS

RIC leverages InteleOne to offer range of services to hospitals, emergency departments

Intelerad Medical Systems, a recognized leader in medical imaging PACS and workflow solutions, today announced that Radiology Imaging Consultants, SC will be leveraging InteleOne to offer a new range of services, including full overnight coverage with final interpretation to hospitals and emergency departments. RIC is a large radiology practice with 75 radiologists reading and reporting over 850,000 studies per year throughout Illinois, Indiana, and Kentucky.

9 Jun 2010

Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced Phase 1 data for its novel heart failure Positron Emission Tomography (PET) imaging agent, LMI 1195, which is in development for the evaluation of patients at risk of heart failure or sudden cardiac death.

9 Jun 2010

Immunosignature technique provides pre-symptomatic diagnosis for broad range of ailments

An inexpensive system for earlier disease diagnosis could save innumerable lives. It would also have a profound impact on the nation's healthcare industry, currently buckling under the strain of spiraling costs.

9 Jun 2010

Breast tomosynthesis holds promise for early breast cancer detection

In the U.S., one out of eight women will develop breast cancer in her lifetime. The earlier the breast cancer is found, the more likely a woman will live a normal life, said Stephen Rose, M.D., a breast radiologist at Memorial Hermann Memorial City.

9 Jun 2010

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

GE Healthcare, a unit of the General Electric Company, today will present results of a phase 1 study of anti-[18F]FACBC at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah. The presentation closely follows the launch of the phase 2 clinical development program for anti-[18F]FACBC, which was initially discovered and developed by Emory University, Atlanta, Georgia, and was licensed to Nihon Medi-Physics Co., Ltd. (NMP) of Japan.

9 Jun 2010

Patient Home Monitoring to trade under ticker symbol "PHM" on TSX Venture Exchange

Patient Home Monitoring, a company focused on in-home cardiology healthcare services, today announced that it will begin trading under the ticker symbol "PHM" on the TSX Venture Exchange at the open of market today, Tuesday, June 8, 2010.

8 Jun 2010

Health-care cost for patients after stroke soars to more than $2.5 billion a year in Canada: Study

Health-care costs for patients in just the first six months after they have a stroke is more than $2.5 billion a year in Canada, according to a study presented today at the Canadian Stroke Congress.

8 Jun 2010

Clarient granted U.K. patent for TLE3 biomarker

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company's TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy.

8 Jun 2010

Top 10 tips to avoid medical mistakes

In this new original and eye-opening book, THE NOT SO PATIENT ADVOCATE: How To Get The Healthcare You Need Without Fear Or Frustration, readers walk through the seemingly forbidden or secretive door to the mystifying and occasionally infuriating maze that is today's healthcare machine. The author shares candid facts about what actually goes on where healthcare interaction occurs.

8 Jun 2010

Optical coherence tomography shows promise for multiple sclerosis diagnosis

A quick, painless eye measurement shows promise as a way to diagnose multiple sclerosis in its very early stages, and to track the effectiveness of treatments, researchers from UT Southwestern Medical Center have found in a multicenter study.

8 Jun 2010

Researchers discover RAF oncogene that may drive aggressive forms of prostate cancer

The Prostate Cancer Foundation announced today that researchers at the University of Michigan Comprehensive Cancer Center have discovered the RAF oncogene that drives fatal melanomas may also drive the aggressive forms of prostate cancer in the clinic.

8 Jun 2010

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced preliminary data from a single site participating in the multicenter Phase 2 clinical trial that showed that Positron Emission Tomography (PET) imaging with its novel investigational agent flurpiridaz F 18 injection (formerly known as BMS747158) provided better image quality than technetium-99m sestamibi single photon emission computed tomography (SPECT), the current standard for the non-invasive detection of coronary artery disease (CAD).

8 Jun 2010

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix Biomedical today reported new data further demonstrating that its DNA blood tests have the potential to accurately detect early stage breast and prostate cancers. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

8 Jun 2010

30 percent of Aussie mums think it’s OK to drink alcohol while pregnant

A new Australian study has revealed an alarming trend showing one in three pregnant or breastfeeding woman are still drinking alcohol. The Alcohol Education and Rehabilitation Foundation (AERF) feel that in spite of warnings to pregnant women to cut out alcohol completely from their diets, many women are ignoring such warnings.

7 Jun 2010

Lawsuit to be launched over breast cancer gene patent

BRCA1 and BRCA2 are two genes that have been identified to hold a key to women’s susceptibility to get breast or ovarian cancer. Changes also known as mutations in these genes are significant in women who go on to develop breast or ovarian cancer. Melbourne-based company Genetic Technologies Limited (GTL) has the exclusive license from American biotechnology company Myriad Genetics to carry out testing for the genes in Australia. Myriad holds a patent for these genes.

7 Jun 2010

Watermark Medical completes $15M equity investment from CA Technologies

Watermark Medical, Inc., a privately-held medical products and services company currently servicing the sleep-disordered breathing market, today announced the completion of a $15 million equity investment from CA Technologies. This equity investment in Watermark Medical represents CA Technologies' entry into the emerging Software-as-a-Service -based healthcare cloud market.

7 Jun 2010

CompuMed, CSHC partner to promote CardioGram and CardioGramKids ECG for school health centers

CompuMed, Inc., a telemedicine and medical informatics company, has partnered with the nonprofit California School Health Centers Association to promote CompuMed's CardioGram and CardioGramKids electrocardiogram telemedicine technologies for use in school health centers throughout California.

7 Jun 2010

SunTech Medical named Rookie Vendor of the Year

SunTech Medical was named 'Rookie Vendor of the Year' at Medline Industries, Inc.'s annual meeting for their HealthCare sales division in Montgomery, Texas. SunTech supplies Medline with the 247 Diagnostic Station, a blood pressure device that can also serve as a vital signs monitor, which Medline distributes to nursing homes and hospitals across the United States.

7 Jun 2010

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Chronix Biomedical today reported new data further demonstrating that its serum DNA blood tests have the potential to accurately detect early stage breast cancer and prostate cancer. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on circulating DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

7 Jun 2010

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Cancer diagnostics company Biomoda, Inc. has been granted a Mexican patent for its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light.

7 Jun 2010

Diagnostic News and Research

RIC leverages InteleOne to offer range of services to hospitals, emergency departments

Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent

Immunosignature technique provides pre-symptomatic diagnosis for broad range of ailments

Breast tomosynthesis holds promise for early breast cancer detection

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

Patient Home Monitoring to trade under ticker symbol "PHM" on TSX Venture Exchange

Health-care cost for patients after stroke soars to more than $2.5 billion a year in Canada: Study

Clarient granted U.K. patent for TLE3 biomarker

Top 10 tips to avoid medical mistakes

Optical coherence tomography shows promise for multiple sclerosis diagnosis

Researchers discover RAF oncogene that may drive aggressive forms of prostate cancer

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

30 percent of Aussie mums think it’s OK to drink alcohol while pregnant

Lawsuit to be launched over breast cancer gene patent

Watermark Medical completes $15M equity investment from CA Technologies

CompuMed, CSHC partner to promote CardioGram and CardioGramKids ECG for school health centers

SunTech Medical named Rookie Vendor of the Year

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News